Journal of Diabetes Research / 2015 / Article / Fig 2

Review Article

The Place of Dipeptidyl Peptidase-4 Inhibitors in Type 2 Diabetes Therapeutics: A “Me Too” or “the Special One” Antidiabetic Class?

Figure 2

Putative cytoprotective effects of dipeptidyl peptidase-4 inhibitors on organs/tissues targeted by diabetes, including the heart, vessels, kidney, and retina, that are associated with serious diabetic complications.

We are committed to sharing findings related to COVID-19 as quickly and safely as possible. Any author submitting a COVID-19 paper should notify us at help@hindawi.com to ensure their research is fast-tracked and made available on a preprint server as soon as possible. We will be providing unlimited waivers of publication charges for accepted articles related to COVID-19.